Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Bronchial Asthma

Interventions

DRUG

GW815SF Salmeterol/Fluticasone propionate(HFA MDI)

Trial Locations (3)

GSK Clinical Trials Call Center, Setagaya, Tokyo

GSK Clinical Trials Call Center, Funabashi, Chiba

GSK Clinical Trials Call Center, Takasaki, Gunma